With 1.4 million dengue cases reported this year, Brazil stands to gain tremendous value from this new dengue prevention tool
Sanofi Pasteur, the vaccines division of Sanofi, announced that Brazil has granted regulatory approval to Dengvaxia, representing the third successful licensure of the dengue vaccine, which was also approved in Mexico and the Philippines earlier this month.
The Brazilian regulatory authorities ANVISA approved Dengvaxia, tetravalent dengue vaccine, for the prevention of disease caused by all four dengue types in individuals from nine to 45 years of age living in endemic areas.
Dengue continues to hit hard in Brazil with over 1.4 million Brazilians directly affected by the disease during this year’s outbreak season alone. Up to 70 per cent of dengue cases in Brazil are reported in individuals nine years and older, a highly mobile and socially active segment of the population who contributes to the spread of the disease within communities.
Dengvaxia was shown to reduce dengue due to all four serotypes in two-thirds of the participants and prevent eight out of 10 hospitalisations due to dengue and up to 93 per cent of severe dengue cases.